Clicky

AstraZeneca PLC(AZN) News

Date Title
Jun 17 Astrazeneca (AZN) Stock Sinks As Market Gains: Here's Why
Jun 17 EHA 2024: AstraZeneca’s Calquence plus chemoimmunotherapy offers new standard for MCL
Jun 17 AstraZeneca's (AZN) Imfinzi Gets FDA Nod in Expanded Use
Jun 17 IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
Jun 17 AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval
Jun 17 AstraZeneca reports positive data from Phase III mantle cell lymphoma trial
Jun 17 AstraZeneca/Fibrogen’s Roxadustat FDA Review Further Delayed Following Unanticipated Advisory Committee Request
Jun 16 CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
Jun 14 Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Jun 14 Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
Jun 13 AstraZeneca CFO: 'We've come a long way in our oncology portfolio'
Jun 13 FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D
Jun 13 Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
Jun 13 FDA approves AstraZeneca’s Farxiga for paediatric T2D patients
May 14 PRESS DIGEST-British Business - May 14
May 13 UK pharma giants pledge £430m investment in France after Macron charm offensive
May 13 Update: AstraZeneca Sued by Trial Participant For Alleged Injury During COVID-19 Vaccine Study
May 13 Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
May 13 France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit
May 12 Forget Johnson & Johnson: Buy This Better Healthcare Stock Instead